These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 25032885)

  • 1. Pharmacotherapy for hyperammonemia.
    Hadjihambi A; Khetan V; Jalan R
    Expert Opin Pharmacother; 2014 Aug; 15(12):1685-95. PubMed ID: 25032885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevention and treatment of hepatic encephalopathy].
    Sivolap YP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
    Ahire K; Sonawale A
    J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nontraditional Treatment of Hepatic Encephalopathy.
    Singh J; Ibrahim B; Han SH
    Clin Liver Dis; 2024 May; 28(2):297-315. PubMed ID: 38548441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure.
    Kristiansen RG
    Metab Brain Dis; 2016 Dec; 31(6):1357-1358. PubMed ID: 27651377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy.
    Jalan R; Wright G; Davies NA; Hodges SJ
    Med Hypotheses; 2007; 69(5):1064-9. PubMed ID: 17467190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the Therapeutic Management of Hepatic Encephalopathy.
    Kornerup LS; Gluud LL; Vilstrup H; Dam G
    Curr Gastroenterol Rep; 2018 Apr; 20(5):21. PubMed ID: 29644492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms, diagnosis and management of hepatic encephalopathy.
    Prakash R; Mullen KD
    Nat Rev Gastroenterol Hepatol; 2010 Sep; 7(9):515-25. PubMed ID: 20703237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond Lactulose: Treatment Options for Hepatic Encephalopathy.
    Said VJ; Garcia-Trujillo E
    Gastroenterol Nurs; 2019; 42(3):277-285. PubMed ID: 31145253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of hepatic encephalopathy in the hospital.
    Leise MD; Poterucha JJ; Kamath PS; Kim WR
    Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifaximin for treatment of hepatic encephalopathy.
    Maclayton DO; Eaton-Maxwell A
    Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycine and hyperammonemia: potential target for the treatment of hepatic encephalopathy.
    Kristiansen RG; Rose CF; Ytrebø LM
    Metab Brain Dis; 2016 Dec; 31(6):1269-1273. PubMed ID: 27339764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
    Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
    Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the treatment of hyperammonemia.
    Matoori S; Leroux JC
    Adv Drug Deliv Rev; 2015 Aug; 90():55-68. PubMed ID: 25895618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hyperammonemia in liver failure.
    Jover-Cobos M; Khetan V; Jalan R
    Curr Opin Clin Nutr Metab Care; 2014 Jan; 17(1):105-10. PubMed ID: 24281376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Overt Hepatic Encephalopathy.
    Sussman NL
    Clin Liver Dis; 2015 Aug; 19(3):551-63. PubMed ID: 26195208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clearance and production of ammonia quantified in humans by constant ammonia infusion - the effects of cirrhosis and ammonia-targeting treatments.
    Eriksen PL; Djernes L; Vilstrup H; Ott P
    J Hepatol; 2023 Aug; 79(2):340-348. PubMed ID: 37061198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study.
    Poo JL; Góngora J; Sánchez-Avila F; Aguilar-Castillo S; García-Ramos G; Fernández-Zertuche M; Rodríguez-Fragoso L; Uribe M
    Ann Hepatol; 2006; 5(4):281-8. PubMed ID: 17151582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic encephalopathy.
    Khungar V; Poordad F
    Clin Liver Dis; 2012 May; 16(2):301-20. PubMed ID: 22541700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes.
    Rahimi RS; Brown KA; Flamm SL; Brown RS
    Am J Med; 2021 Nov; 134(11):1330-1338. PubMed ID: 34242619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.